Senescent cells in the development of cardiometabolic disease

Andrea C. Postmus, Ines Sturmlechner, Johan W. Jonker, Jan M. Van Deursen, Bart Van De Sluis, Janine K. Kruit

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Purpose of reviewSenescent cells have recently been identified as key players in the development of metabolic dysfunction. In this review, we will highlight recent developments in this field and discuss the concept of targeting these cells to prevent or treat cardiometabolic diseases.Recent findingsEvidence is accumulating that cellular senescence contributes to adipose tissue dysfunction, presumably through induction of low-grade inflammation and inhibition of adipogenic differentiation leading to insulin resistance and dyslipidaemia. Senescent cells modulate their surroundings through their bioactive secretome and only a relatively small number of senescent cells is sufficient to cause persistent physical dysfunction even in young mice. Proof-of-principle studies showed that selective elimination of senescent cells can prevent or delay the development of cardiometabolic diseases in mice.SummaryThe metabolic consequences of senescent cell accumulation in various tissues are now unravelling and point to new therapeutic opportunities for the treatment of cardiometabolic diseases.

Original languageEnglish (US)
Pages (from-to)177-185
Number of pages9
JournalCurrent opinion in lipidology
Issue number3
StatePublished - Jun 1 2019


  • cardiometabolic disease
  • cellular senescence
  • insulin resistance
  • metabolic syndrome
  • senolytics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Genetics
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine
  • Cell Biology


Dive into the research topics of 'Senescent cells in the development of cardiometabolic disease'. Together they form a unique fingerprint.

Cite this